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Transfusion in trauma: why and how should we change our
current practice?
Abstract
PURPOSE OF REVIEW: Major trauma is often associated with hemorrhage and transfusion of blood
and blood products, which are all associated with adverse clinical outcome. The aim of this review is to
emphasize why bleeding and coagulation has to be monitored closely in trauma patients and to discuss
the rationale behind modern and future transfusion strategies. RECENT FINDINGS: Hemorrhage is a
major cause of early death after trauma. Apart from the initial injuries, hemorrhage is significantly
promoted by coagulopathy. Early identification of the underlying cause of hemorrhage with coagulation
tests (routine and bedside) in conjunction with blood gas analysis allow early goal-directed treatment of
coagulation disorders and anemia, thereby stopping bleeding and reducing transfusion requirements.
These treatment options have to be adapted to the civilian and noncivilian sector. Transfusion of blood
and its components is critical in the management of trauma hemorrhage, but is per se associated with
adverse outcome. Decisions must weigh the potential benefits and harms. SUMMARY: Future
transfusion strategies are based on early and continuous assessment of the bleeding and coagulation
status of trauma patients. This allows specific and goal-directed treatment, thereby optimizing the
patient's coagulation status early, minimizing the patient's exposure to blood products, reducing costs
and improving the patient's outcome.
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Abstract  
Purpose of review: Major trauma is often associated with hemorrhage and transfusion of 
blood and blood products, all associated with adverse clinical outcome. The aim of this 
review is to emphasize why bleeding and coagulation has to be monitored closely in 
trauma patients and to discuss the rationale behind modern and future transfusion 
strategies.  
Recent findings: Hemorrhage is a major cause of early death after trauma. Besides the 
initial injuries, hemorrhage is significantly promoted by coagulopathy. Early 
identification of the underlying cause of hemorrhage with coagulation tests (routine and 
bedside) in conjunction with blood gas analysis allow early goal-directed treatment of 
coagulation disorders and anemia thereby stopping bleeding and reducing transfusion 
requirements. These treatment options have to be adapted to the civilian and non civilian 
sector. Transfusion of blood and its components is critical in the management of trauma 
hemorrhage, but is per se associated with adverse outcome. Decisions must weigh the 
potential benefits and harms.  
Summary: Future transfusion strategies are based on early and continuous assessment of 
the bleeding and coagulation status of trauma patients. This allows specific and goal-
directed treatment, thereby optimizing patient’s coagulation status early, minimizing 
exposure to blood products, reducing costs and improving patient’s outcome. 
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Introduction 
Hemorrhage is known to be a major cause of early death after injury and has been shown 
to be responsible for 30% to 40% of trauma mortalities 1-3. Furthermore, hemorrhage with 
consecutive multiple transfusions has been shown to significantly worsen clinical 
outcomes.4,5  
Management priorities in trauma patients are to ensure adequate ventilation, oxygen 
delivery, hemorrhage control and to restore tissue perfusion to vital organs. Early and 
continuous re-assessment of the bleeding and coagulation status of trauma patients allows 
specific goal-directed treatment, thereby optimizing patient’s coagulation status, 
minimizing exposure to blood products, reducing costs and improving patient’s 
outcome.6,7 
 
Mechanism of hemorrhage in trauma patients 
Hemorrhage reduces preload required to ensure adequate cardiac output and peripheral 
oxygen delivery. Inadequate tissue perfusion, not always associated with overt 
hypotension, can trigger a neuro-humoral cascade, leading to sequential organ failure. 
Mortality from established organ failure has not changed since it was first described 
almost 30 years ago 8. Diagnosing and treating hemorrhage early remains imperative. The 
American College of Surgeons has developed the classification scheme stratifying blood 
loss from Stage 1 (<15% of total circulating blood volume) to Stage 4 (>40% of total 
circulating blood volume) 9. Young people in good health may compensate well for large-
volume blood loss, up to 50% of the total circulating blood volume. Then, they may 
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develop sudden cardiovascular compromise when compensatory mechanisms fail. Elderly 
people on the other side may tolerate much smaller blood losses only.  
Anatomical bleeding 
Active hemorrhage as a result of major injuries is life-threatening and leads to 
hemorrhagic shock and exsanguination if not treated readily. Bleeding may be stopped 
temporarily by external compression and tourniquets, however, surgical or interventional 
(e.g., arterial embolization) repair is required for final hemorrhage control. 
 
Coagulopathic bleeding 
An abnormal coagulation status is frequently present early after major trauma at 
admission to the emergency department and is associated with a 5-fold increase in 
mortality 10-13. Traditionally, the acute traumatic coagulopathy has been thought to be due 
to consumption of coagulation factors, dilution from intravenous fluid therapy, 
hypothermia, and metabolic acidosis. However, it has recently been shown that none of 
these factors is initially responsible for the acute traumatic coagulopathy. These factors 
become significant only in the later phase of traumatic coagulopathy. Studies by Brohi et 
al 11-14 have described an early and previously unknown acute traumatic coagulopathy 
before any of the above mentioned traditional causes (lethal triade) of acute traumatic 
coagulopathy were present. These studies have shown that coagulopathy and mortality as 
well as transfusion requirements are to by linked with hypoperfusion of tissues and the 
protein c-pathway, this was also proven for traumatic brain injury. Low protein C levels 
are associated with prolongation of the partial thromboplastin and prothrombin times and 
hyperfibrinolysis with low levels of plasminogen activator inhibitor-1 and high D-dimer 
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levels. High thrombomodulin and low protein C levels are associated with increased 
mortality, blood transfusion requirements, acute renal injury, and reduced ventilator-free 
days. 
The pathophysiology of fibrinolysis in association with injury is exacerbated by shock 
and this is mediated by deinhibition of tissue plasminogen activator through the 
consumption of plasminogen activator inhibitor-1. A low level plasminogen activator 
inhibitor-1, in combination with an increased release of plasminogen activators from the 
vessel wall will result in hyperfibrinolysis. Actually it seems that thrombin activatable 
fibrinolysis inhibitor is the main driver of fibrinolysis inhibition, and that reduction in 
thrombin activatable fibrinolysis inhibitor activation by the competitive binding of 
protein C to thrombin–thrombomodulin is the mechanism for derepression of fibrinolysis 
with activation of protein C. The consumption of plasminogen activator inhibitor-1 by 
activated protein C seems to be the most important clinical cause of hyperfibrinolysis. 
 
Diagnosis and monitoring of bleeding 
Assessment of hemorrhage and volume status. Blood pressure and heart rate are vital 
signs which are nonspecific to evaluate hemorrhage. Mixed and central venous oxygen 
saturation are more sensitive and reliable measurements of acute volume loss 15-17. The 
degree of metabolic acidosis, as measured by the base deficit from an arterial blood gas 
sample, is helpful to evaluate the degree of shock. Base deficit has been shown to 
correlate with transfusion requirements, ICU stay, and ultimate outcome 18,19. During 
initial resuscitation, base deficit typically correlates with serum lactate level. 
Interestingly, the ability to clear lactate to normal is one of the most important predictors 
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of survival following hemorrhage and injury 20-22. Serial blood gas determinations 
(arterial and venous) may be helpful in determining whether blood loss is continuing or 
not.  
 
Assessment of coagulation. Most commonly, routine laboratory-based coagulation tests 
(e.g., PT/INR, aPTT, fibrinogen), platelet numbers and hemoglobin concentration (Hb) 
are being used to assess the patients’ current coagulation status 23. However, the value of 
these tests has been questioned in the acute bleeding situation because there are delays 
from blood sampling to obtaining results (45–60 min), coagulation tests are determined in 
plasma rather than whole blood, no information is available on platelet function and the 
assays are performed at a standard temperature of 37°C rather than the patient’s 
temperature 24. 
Point-of-care coagulation monitoring devices assessing the viscoelastic properties of the 
developing clot in whole blood, e.g., thrombelastography (TEG®) or rotation 
thrombelastometry (ROTEM®), may overcome several limitations of routine coagulation 
tests 25,26. In particular, these technologies allow to assess in vivo coagulation system 
interactions with platelets and red blood cells and provide useful information on platelet 
function 27. In addition, they may be performed at the bedside allowing faster turnaround 
times. Furthermore, the clot development can be visually displayed in real-time, the assay 
is fibrinolysis sensitive, and the coagulation analysis can be done at the patient’s 
temperature 28. Nevertheless, results obtained from these in vitro tests must be carefully 
interpreted in the clinical context. 
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Present and future transfusion practice in trauma patients  
Prevention of further bleeding  
The initial phase after trauma - from injury to surgery/intervention – has to be minimized 
and further bleeding should be prevented. Hill et al 29 observed a significant decrease in 
mortality from shock by establishing a 60 minute emergency department time limit for 
patients in hemorrhagic shock. Additionally, Hoyt et al 30 showed that delayed transfer to 
theatre is an avoidable cause of death which can be minimized by reducing the time for 
diagnosis and resuscitation prior to surgery.  
Without brain injury, a target systolic blood pressure of 80 to 100 mm Hg should be 
maintained until the major bleeding is stopped.6 Aggressive fluid therapy to preserve 
tissue oxygenation and to restore the circulating blood volume leads to dilution of 
coagulation factors, hypothermia, increased hydrostatic pressure and further bleeding. 
The concept of low-volume fluid resuscitation, called ‘permissive hypotension’, prior to 
surgical source contol maintains tissue perfusion at a lower level but sufficient for a short 
period of time without the adverse effects mentioned above 31. The low-volume approach 
is not to be applied in traumatic brain and spinal injuries as an adequate perfusion 
pressure is crucial to ensure tissue oxygenation of the injured central nervous system.  
 
Transfusion of red blood cells (RBC) 
Hemoglobin based transfusion triggers. According to current guidelines from the 
American Society of Anesthesiologist, RBC transfusion is recommended if the 
hemoglobin concentration drops below 6-10g/dl. Transfusions over 10 g/dl are rarely 
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indicated and, transfusions seem almost always indicated if hemoglobin falls below 6 
g/dl. 32 In Europe, a Hb target range of 7-9 g/dL is largely accepted in major trauma.6 
Physiological transfusion triggers on the other hand are tachycardia, hypotension, 
oxygen extraction greater than 50%, mixed venous oxygen pressure of less than 32 mm 
Hg, increase of lactate and ECG changes 6,33,34. The depth of shock, hemodynamic 
response to resuscitation, and the rate of actual blood loss in the acutely bleeding and 
hemodynamically unstable patient may also be integrated into the indication for RBC 
transfusion35. However, RBC transfusions should be used restrictively 36. 
 
Alternatives to allogeneic red cell transfusion  
In trauma, the only available alternative to allogeneic RBC transfusion in clinical practice 
is currently the intraoperative cell salvage. It has been shown efficacious for reducing 
allogeneic blood transfusions 37. The quality of salvaged blood seems to be better 
compared with stored packed RBCs, with less risk for the patient 37. However, cell 
salvage is only applicable when the operative site not contaminated. 
Artificial oxygen carriers may represent a future alternative to RBC transfusions. There 
are two groups of artificial oxygen carrier currently under development: Synthetically 
manufactured perfluorocarbons, and hemoglobin-based oxygen carriers 38. However,none 
of these products has achieved market approval for Europe, US or Canada so far. 
 
Transfusion of fresh frozen plasma (FFP) and platelets 
Traditional indications for fresh frozen plasma are massive bleeding due to multiple 
factor deficiencies, emergency reversal of vitamin K antagonists, and treatment of 
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thrombotic thrombocytopenic purpura (TTP) 32. However, the clinical efficacy of FFP is 
largely unproven6,39. Large quantities of FFP (15 ml/kg body weight and more) are 
recommended to achieve an effect in massive bleeding 6,40,41,. Interestingly, there are only 
expert-opinion but no evidence based transfusion thresholds published for FFP 
administration 32,42. However, there are significant adverse effects associated with FFP 
transfusions including volume overload (TACO), allergic reactions, transfusion-related 
acute lung injury (TRALI), transmission of infectious pathogens 40,43,44 and a 3 fold 
increase of nosocomial infections 45. 
In a bleeding patient, platelets should be kept >50 x 103 /μl, and >100 103 /μl in patients 
with traumatic brain injury 6,7. Adverse effects of platelets are similar to FFP, except the 
much higher risk of bacterial contamination 46. Therefore, the indication to transfuse 
platelets is to be restrictive. As for FFP, there are only expert-opinions available for the 
indication of platelet transfusion, no studies on an evidence based level are available so 
far. 
 
Replacement of specific coagulation factors 
Fibrinogen. Fibrinogen is the substrate to form a clot. Several in-vitro and animal studies 
have shown that fibrinogen substitution is essential to reverse dilutional coagulopathy 47-
49. Furthermore, several human studies (civilian and non-civilian) confirmed these data, 
showing that early and aggressive replacement of fibrinogen in patients with severe 
hemorrhage and dilutional coagulopathy improves clot strength significantly and may 
lead to better survival 50-53. 
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Factor XIII. Factor XIII is the key coagulation factor to stabilize the clot. Schroeder et al 
and Nielsen et al 54-56 have proven a relation between decreased factor XIII activity and 
reduced clot firmness (MCF) by computerized thrombelastography. Trauma and major 
hemorrhage is known to be a cause of acquired factor XIII deficiency 57. It seems 
reasonable to substitute factor XIII early, thereby improving clot firmness and reducing 
bleeding 58 as well as the use of blood products 59,60.  
 
Prothrombin complex concentrate. Prothrombin complex concentrates (PCC) provide a 
source of the four vitamin K dependent coagulation factors, and consequently, PCC is 
recommended both in Europe and the USA for emergent reversal of oral anticoagulants 
61-65. Furthermore, Bruce and Nokes 66 recently demonstrated that the use of PCC in 
trauma patients leads to a considerable reduction in the use of blood products (FFPs, 
RBCs and cryoprecipitate) and that survival improved and bleeding stopped earlier. 
Therefore, PCC might have a place in control of trauma related bleeding, although this 
indication is currently off label. 
 
rFVIIa. Recombinant activated factor VIII (rFVIIa) leads to a “thrombin burst” thereby 
transforming fibrinogen into fibrin. Before treating patients with rFVIIa, patients should 
fulfill certain criteria, for example thrombocytopenia and hypofibrinogenemia must be 
corrected 67-69. One study in trauma has shown a reduction in RBC transfusions in rFVIIa 
treated patients 70. However, rFVIIa is not an alternative to surgical bleeding control, and 
its use in trauma is still an off label indication. Risks and benefits have to be carefully 
evaluated before usage and economic aspects taken into consideration 71.  
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Pharmacologic agents  
Antifibrinolytics, such as aminocaproic acid (ε-aminocaproic acid) and tranexamic acid 
are used to inhibit overt fibrinolysis, which act by blocking the lysine-binding site on 
plasmin. 6  
 
Protamine sulfate reverses the anticoagulant effects of heparin by binding to it. It is a 
highly cationic peptide. It binds to heparin to form a stable ion pair which does not have 
anticoagulant activity.  
 
Specific goal-directed transfusion, transfusion algorithms 
Algorithms display decision-making treatment processes and problem-solving strategies 
by giving clearly defined and formalized guidelines. With the help of clinical algorithms, 
highly complex processes such as the management of the bleeding can be translated into 
a clearly structured, logical pathway.72 Specific goal-directed transfusion can be achieved 
by using such algorithms, leading to a reduction of blood component used and to a 
possible better outcome by stopping bleeding in trauma early. 
At our institution, we recently implemented a transfusion algorithm for massively 
bleeding patients (Figure 1). This algorithm incorporates information obtained from 
patient’s history, clinical presentation, routine coagulation laboratory and bed-site 
viscoelastic coagulation testings. Interestingly, our experience implementing and 
adhering to a transfusion algorithm is in accordance with previous studies showing 
significant reduction in number of transfusion administered, decrease of blood loss and 
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costs 27,72,73. For example, in the first 6 months after implementation of the algorithm, the 
use of FFP dropped by approximately 50% and RBC as well as platelet administration 
decreased by approximately 20% each. Despite a moderate increase in costs for point-of-
care coagulation monitoring and more frequent administration of specific coagulation 
factor concentrates (fibrinogen, factor XIII, PCC, rFVIIa), we had a significant cost 
savings in this first 6 months after implementing our algorithm.  
 
Adverse effects of transfusion 
The administration of blood products is associated with adverse effects 74 including viral 
or bacterial 75 transmission. This is perceived to be under control in developed countries 
76. However, there are other issues. RBC transfusion has been found to be a highly 
significant and independent factor for an increased mortality and morbidity in a variety of 
surgical situations 77. Also nosocomial infections are several fold more frequent in 
transfused vs. non-transfused patients.45,78,79  Transfusion-related acute lung injury 
(TRALI) is another risk 80,81 occurring during or within 6 hours of transfusion 82. The risk 
for TRALI is estimated to be 1 in 1000 to 1 in 4000 units transfused with a significant 
mortality 82. Immune suppression or modulation potentially associated with multi organ 
failure (MOF) and an increased cancer recurrence is another adverse effect of allogeneic 
blood transfusions 83-85, particularly with long storage times.86  
 
Differences between civilian and non civilian sector  
In recent publications of the US military the use of fresh whole blood has been described 
for soldiers with life threatening injuries. Spinella found that surviving improved 48 
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hours and 30 days after whole blood transfusion compared to massive transfusion of 
stored red cells.87,88 The risk of transmission of infectious agents and other 
microorganisms remains higher for fresh whole blood then RBCs. In the civilian sector 
such protocols thus are not applicable. 
Trauma exsanguination protocols like the one of Cotton89 try to create whole blood 
conditions by transfusion fix amounts of RBCs, FFP and platelets. However, this does not 
seem to be an adequate strategy in civilian trauma managment, the goal to achieve must 
be a specific management and replacement of blood components and factors according to 
on-line bed-side coagulation monitoring which may not be feasible in a military 
environment. 
 
Conclusion 
Although a lot of progress has been made in the field of trauma patients, treatment of 
massive bleeding still remains an interdisciplinary challenge for surgeons and 
anesthesiologist. Modern and future transfusion strategies are based on on-line bed-side 
coagulation monitoring with specific goal-directed administration of anti-fibrinolytics, 
coagulation factors, RBC, fresh frozen plasma and platelets to optimize coagulation early. 
This allows improving patient’s outcome, minimizing exposure to blood products and 
reducing costs. 
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